Clinicians' Use of Intravaginal Boric Acid Maintenance Therapy for Recurrent Vulvovaginal Candidiasis and Bacterial Vaginosis
- PMID: 31663976
- PMCID: PMC6878170
- DOI: 10.1097/OLQ.0000000000001063
Clinicians' Use of Intravaginal Boric Acid Maintenance Therapy for Recurrent Vulvovaginal Candidiasis and Bacterial Vaginosis
Abstract
A retrospective chart review characterized clinicians' use of maintenance intravaginal boric acid for women with recurrent vulvovaginal candidiasis or bacterial vaginosis. Average length of use was 13 months with high patient satisfaction and few adverse events. Prospective studies are needed to evaluate the efficacy of maintenance boric acid for these conditions.
Conflict of interest statement
References
-
- Sobel JD, Sobel R. Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species. Expert Opin Pharmacother 2018;19(9):971–7. - PubMed
-
- Iavazzo C, Gkegkes ID, Zarkada IM, et al. Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence. J Womens Health (Larchmt) 2011;20(8):1245–55. - PubMed
-
- Lefebvre MA, Quach C, Daniel SJ. Chronic suppurative otitis media due to nontuberculous mycobacteria: A case of successful treatment with topical boric acid. Int J Pediatr Otorhinolaryngol 2015;79(7):1158–60. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
